Malaria Therapeutic Efficacy Study, Rwanda
NCT04767217
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
528
Enrollment
OTHER
Sponsor class
Conditions
Uncomplicated Malaria
Interventions
DRUG:
artemether-lumefantrine (ALN)
DRUG:
dihydroartemisinin-piperaquine (DHA-PPQ)
Sponsor
Jhpiego
Collaborators
[object Object]
[object Object]
[object Object]